Introduction
Catheter ablation can cure different types of cardiac arrhythmia. [1] [2] [3] [4] Nowadays up to 600 patients per one million population receive this treatment worldwide annually. 5 Most ablation procedures are undertaken for supraventricular tachycardia (SVT) including atrial fibrillation (AFIB), focal atrial tachycardia (focal AT), and various types of re-entrant tachycardia like atrial flutter (AFL), atrioventricular (AV) nodal re-entrant tachycardia (AVNRT), and AV re-entrant tachycardia (AVRT). 1, 2, 6 Although catheter ablation treatment has been extensively evaluated in specific subgroups and in controlled trials, less is known about the real-world outcome in a large multicentric cohort. [7] [8] [9] [10] [11] [12] [13] The
German Ablation Quality Registry was therefore initiated to study procedural performance and clinical outcome of catheter ablation for SVT in routine clinical practice.
Methods
The registry prospectively collected data on cardiac ablation procedures performed between January 2007 and January 2010. Fifty-two voluntarily participating German centres committed themselves to include all consecutive consented patients. The aim was to document:
(1) baseline characteristics of consecutive patients undergoing catheter ablation; (2) ablation methods; (3) procedure outcomes and acute complications; (4) 1-year follow-up data on mortality, adverse events, repeat ablation, and freedom from arrhythmia; (5) drugs at discharge and during follow-up; (6) patient satisfaction and symptomatic improvement at 1 year.
The registry was industry-independently financed by the Foundation Stiftung Institut für Herzinfarktforschung (Stiftung IHF) in Ludwigshafen, Germany. The Stiftung IHF was responsible for project development, project management, clinical monitoring, patient follow-up, and data management. The follow-up > _1 year was also conducted and largely funded by the Stiftung IHF, with additional support by unrestricted grants from Medtronic, Biosense Webster, and Biotronik. The study was approved by the ethics committee of the Landesaerztekammer Rheinland-Pfalz in 2007 .
Data collection
Participating centres reported data from consenting patients in Internetbased electronic case report forms. All site information was confidential, and transmitted data were encrypted with a secure socket layer. At baseline, patient age, gender, symptoms, details of cardiac disease, and comorbidities were noted. Patients were treated according to the ablation centre standards. The decision regarding the ablation method, imaging technologies, energy source, and procedural endpoints was left to the choice of the individual ablation centre. During 'index' hospital stay, a single (de novo or repeat) ablation procedure or more procedures were performed. Procedural data were recorded, including cumulative ablation time, fluoroscopy time, dose area product, and total procedure duration, always including basic electrophysiology study.
The ablating operators routinely classified primary success as full, partial (not all morphologies), or no success based on their institutional or personal standards, derived from contemporary clinical guidelines and current scientific evidence. Ablation strategies for AFIB aimed at electrical isolation of the pulmonary veins; in AVNRT at modulation or ablation of the slow pathway; in cavotricuspid isthmus dependent AFL at complete, permanent bidirectional conduction block across the isthmus; and in AVRT, at conduction block of the accessory pathway. Treatment-related complications were recorded, along with in-hospital arrhythmia recurrence and medication at discharge.
Follow-up schedule, arrhythmia monitoring methods, and criteria for repeat ablation were at the discretion of ablation centres. After > _1 year of enrolment, the patients were contacted over phone by the Stiftung IHF and interrogated about complications, tachycardia recurrences, new ablations, change in symptoms, and subjective perception of the ablation therapy as successful, partly successful, or unsuccessful.
Data analysis and statistical methods
Descriptive statistical analyses were planned and performed, characterising the registry population and subsets of patients defined by different types of arrhythmia. Continuous data are reported as median (inter-quartile range) or mean ± SD. Categorical data are reported as percentages with one decimal point, except for event rates which are presented as both absolute counts and percentages. Cumulative incidence of death and MACCE (combined endpoint comprising death, myocardial infarction, and stroke) after discharge from the index hospitalisation was calculated using the Kaplan-Meier method. Rates of other follow-up events are reported as percentages among survivors. The follow-up duration was defined as the time span from index discharge to the date of the followup contact, i.e. when information on the patient's status was obtained. For proportions 95%-confidence intervals were calculated by the Clopper-Pearson method, for Kaplan-Meier estimates using the delta method with a log-log transformation. The statistics are based on the available cases. The risk of stroke was assessed with the CHADS 2 score, which was calculated regardless of the underlying arrhythmia according to Camm et al. 14 The statistical computations were performed at the biometrics department of the Stiftung IHF using SAS release 9.3 on a personal computer (SAS Institute, Inc., Cary, NC, USA).
Results

Patients and arrhythmias
The registry enrolled 12 566 patients undergoing catheter ablation for SVT between January 2007 and January 2010. A wide span in the median patient age, ranging from 42 years (AVRT) to 68 years (AFL), translated into substantially different patient collectives. The oldest group, those treated for AFL, had the highest prevalence of concomitant cardiac diseases and comorbidities at baseline. Only hypertrophic cardiomyopathy and prior stroke were more prevalent in the AFIB group, and structural heart disease was more prevalent in the focal AT group. Conversely, the youngest group, AVRT, was the least sick despite the highest prevalence of prior syncope (4.9% vs. 1.7-3.2% in other groups).
Ablation for AFIB was typically undertaken after at least one antiarrhythmic drug failed to diminish symptoms. 2 
Acute results
Procedure methods and outcomes are summarised in Table 2 .
Depending on the arrhythmia type, the proportion of de novo ablations varied from 82.3 to 95.5%. The periprocedural success rate was > _94%, except for focal AT (84.3%). Of patients treated for AFIB, 82.5% underwent circumferential pulmonary vein isolation, 11.9% underwent segmental pulmonary vein isolation, 11.3% had ablation of complex fractionated potentials, 16 .4% received linear lesion, and 5.0% had AV node ablation followed by pacemaker implantation. Major in-hospital complications are summarised in Table 3 . Only four patients died. A composite rate of death, stroke, and myocardial infarction (MACCE) ranged from no such event (AVRT and focal AT) to 0.3% (AFIB). Moderate in-hospital complications affected 1.8% of patients: a relevant pericardial effusion was observed in 0.5% of all ablated cases (for AFIB, in 40 out of 4089 patients, or 1.0%). A complete AV block was observed 0.3% of patients ablated for AVNRT.
Follow-up results
One-year follow-up data were obtained from 12 140 (96.6%) out of 12 562 patients discharged alive; 280 (2.3%) patients died during follow-up ( Table 4) . The composite rate of death, stroke, and myocardial infarction was 2.1%. Patients treated for AFL or focal AT had the highest rate of major adverse events ( Figures 1A and 2) .
Re-ablation during 1 year varied from 3.5% (AVNRT group) to 19.4% (AFIB group) ( Table 4 and Figure 1B ). Re-ablation was necessitated by the symptomatic recurrences of the ablated arrhythmia or by the onset of other symptomatic tachycardia. The proportion of patients without arrhythmia in follow-up ranged from 54.4% (AFIB) to 82.8% (AVNRT group) ( Table 4 and Figure 1C ). The long-term use of class I and class III antiarrhythmics was as low as 2-4% in the AVNRT and AVRT groups, and 20-30% in the AFIB, AFL, and focal AT groups ( Table 4) .
Patient perspective on ablation therapy success
After 1 year, 74.1% of interviewed patients perceived ablation therapy as successful, 15 .7% as partly successful, and 9.6% as unsuccessful ( Table 5 ). The most satisfied were patients treated for AVNRT (85.6%) and AVRT (78.7%), and the least satisfied were those treated for AFIB (62.8%). As seen in Figure 1C , patient perspective on ablation Table 5) . Possible symptomatic improvement despite arrhythmia recurrences resulted in a relatively high percentage of patients perceiving ablation as successful (42.4%) or partly successful (33.6%) even in the 'recurrence' group ( Table 6 ). In the 'no arrhythmia' group, 89.8% of patients perceived ablation therapy as successful and 6.9% perceived it as partly successful. Very high proportion of patients would undergo their redo at the same clinic irrespective of whether they had (89.6%) or did not have (96.7%) arrhythmia recurrences.
Discussion
One of the important aspects in registries which determine data quality is data completeness. In our investigation, data was complete in >99.8% for baseline and procedural variables, therefore this information is one of the largest and most complete mulitcentric data sets in SVT ablation available. Follow-up data were gathered in 12 140 patients enrolled, with a data completeness >95% for variables included from study beginning, to adhere to the established institutional goals of the scientific sponsor. 16 
Periprocedural results
The overall periprocedural success rate of SVT ablation was 96.3%. The success rates for different arrhythmia types were equal or slightly higher than the corresponding rates reported from other largevolume registries. 8, 11, 17 This improvement may have been expected Figure 1 Major follow-up outcomes and patient perspective on therapy success. (A) One-year mortality and MACCE rates (Kaplan-Meier estimates) (B) New ablation during 1 year after index discharge (repeat or de novo) (C) Total arrhythmia freedom and patient perspective on ablation therapy success. Patients were followed for at least 1 year (see Table 4 ). † No arrhythmia bars show the absence of all tachycardia types, not only the ablated one. AFIB, atrial fibrillation group; AFL, atrial flutter and other macro re-entrant atrial tachycardia group; AVNRT, atrioventricular nodal reentrant tachycardia group; AVRT, atrioventricular re-entrant tachycardia including Wolff-Parkinson-White Syndrome group; FAT, focal atrial tachycardia; MACCE, major adverse cardiac and cerebrovascular event (death, stroke, or myocardial infarction).
.
based on continuous advancements in ablation techniques and equipment. [18] [19] [20] [21] [22] [23] One of the major messages is that catheter ablation is a safe procedure. We observed in-hospital death rate of approximately 1 per 3000 patients (0.03%), with a minor variation between groups. By comparison, in large patient cohorts described in literature, each comprising 2314 to 9662 patients undergoing all types of ablation procedures, the overall early death rate ranged from no death (Canada 17 undergoing AFIB ablation in years 2001-2006, the early death rates were 0.08-0.40%, or 2-10 times higher than in our patients, who apparently benefited from the improved safety of AFIB ablation in recent years. 26, 27 Also the combined rate of in-hospital non-fatal stroke or myocardial infarction was very low in our registry, approximately 1 in 800 (complete study group); 13 of the 16 MACCE occurred in the AFIB group, with no such events in AVRT or focal AT groups. Data are percentages of patients alive at 1-year follow-up. AFIB, atrial fibrillation; AFL, atrial flutter and other macro re-entrant AT; AT, atrial tachycardia; AVNRT, atrioventricular nodal re-entrant tachycardia; AVRT, atrioventricular re-entrant tachycardia including Wolff-Parkinson-White Syndrome; CHADS 2 , risk of stroke ranging from 0 (low) to 6 (high); COPD, chronic obstructive pulmonary disease; IQR, inter-quartile range; LVEF, left ventricular ejection fraction; SD, standard deviation. 
Follow-up results and patient satisfaction
Mortality During 1-year follow-up, markedly higher mortality was observed in the AFL (2.6%) and focal AT (2.8%) than in other patient groups (0.7-0.9%). The underlying reason in the AFL group is probably the advanced age at baseline (17.4% of AFL patients were older than 75 years vs. 2.2-10.0% in other groups), combined with the highest prevalence of reduced (< _40%) left ventricular ejection fraction (13.4% vs. 1.6-7.3%).
Non-fatal strokes
Most non-fatal strokes during follow-up were observed in the AFL group, with the event rate of 1.3%, vs. 0.0-0.6% in other groups (Table 4) . Importantly, the mean CHADS 2 score at baseline was higher in AFL (1.1 ± 1.0) than in AFIB (0.9 ± 0.9) patients. Nevertheless, at discharge, vitamin K antagonists were less used in AFL (61.5%) than AFIB (89.7%) patients, although AFIB is common also after AFL ablation. 6 This leads to one of the important clinical messages derived from this data set: a more consistent anticoagulation therapy is necessary in patients treated for AFL.
Long-term ablation success
Our long-term ablation success rates were lower than those reported in literature. The likely reason was non-selectivity regarding the type of recurrent arrhythmia, because recurrent arrhythmia was fulfilled when the patient reported this phenomenon following catheter ablation; ECG documentation to determine the nature of the arrhythmia was not systematically performed. Therefore it was not possible to distinguish episodes of AFIB after AFL ablation from real AFL recurrence, whereas other studies determined the relapse of the ablated arrhythmia, as judged by the attending physician based on ECG documentation. (1) AFIB. In a meta-analysis of patients treated for AFIB, the freedom from the arrhythmia recurrence was 57% (after single procedure) or 71% (after multiple procedures) over a mean follow-up of 14 months, off antiarrhythmic drug therapy, 20 as compared with the 41.6% success in our registry, for pooled single and multiple procedures, off antiarrhythmics based on patients report. Likewise, in a world-wide survey, the 71-84% success was observed for different AFIB types after a mean follow-up of 10 months irrespective of the use of antiarrhythmics, 13 as compared with the 54.4% success in the present registry, with or without antiarrhythmics, but after a somewhat longer mean follow-up of 16 months that may per se lead to slightly higher arrhythmia recurrence. [28] [29] [30] (2) AVNRT and AVRT. In a large historical cohort, the ablated arrhythmia recurrence rates following AVNRT or AVRT ablation were 5% (AVNRT) and 8% (AVRT) after a mean follow-up of 6.3 months, 31 vs.
an arrhythmia recurrence rate of 17.2% (AVNRT) and 20.3% (AVRT) in our registry, after a mean follow-up of 19-22 months. We think this can be explained by two major aspects:
(1) There is a difference between recurrence of the ablated arrhythmia and recurrence of any arrhythmia, which may include runs of premature atrial contractions or AFIB. This difference of ablated vs. any arrhythmia has clinical implications: physicians should explain to patients, that symptomatic recurrence after AVRT or AVNRT ablation is occurring in around 1 out of 5 patients. If this happens, it should trigger ECG documentation of the recurrent arrhythmia to determine whether it is recurrence of the ablated arrhythmia (which might create an indication for redo) or recurrent arrhythmia of different nature which may lead to a different therapy. Especially AFIB in elderly patients post-AVNRT ablation should be recognised as AFIB (and should not be misclassified by the patient as a recurrence of AVNRT) because diagnosed AFIB might lead to an indication for oral anticoagulation to prevent stroke. (2) Data completeness in our registry is high and mean follow-up of 19-22 months is significantly longer than other reports, therefore the likelihood of capturing recurrences of ablated or other arrhythmias is higher than in shorter follow-up times.
In addition, the cohort with AVNRT and AVRT demonstrates an unexpected high rate of all-cause rehospitalisation during follow-up. We think that this is explained by a mixture of non-cardiovascular rehospitalisation in this age group but mainly by those patients who undergo reablation (which account for nearly half of the rehospitalized patients) and those who report recurrence of symptomatic tachycardia who are rehospitalized for diagnostic purpose because outpatient care is usually not possible for German hospitals.
Patient satisfaction
The main focus of this data set is to elucidate the effect of catheter ablation as a therapeutical concept to treat SVT mainly to improve quality of life and symptom status. Overall, freedom from any symptomatic tachycardia is 67.4% in 12 140 ablated patients with a minimum follow-up of 1 year. The most favourable outcome is observed in AVNRT, with 82.8% of ablated patients with no recurring symptomatic arrhythmia, the modest outcome is observed in AFIB patients with a symptomatic arrhythmia free level of 54.4%. It is clear that patient reported recurring arrhythmia is a mix of 'true' recurrence of the previous ablated arrhythmia, recurring arrhythmia of a different nature or even no arrhythmia but a true 'missensing' of the patient. Still, catheter ablation is a symptom-oriented treatment modality, therefore its overall performance and outcome-from the patients perspective-is an important information for the clinician.
In the total study group, patients percepted the ablation therapy as successful in 74.1%, partly successful in 15.7% and only 9.6% graded catheter ablation as unsuccessful in their case. This is directly related to the symptom scoring of improvement in 79.9%, only 3.2% felt a worsening of their arrhythmia. This data and patient perception underlines that catheter ablation as a therapeutical concept is highly successful in terms of symptom treatment. Furthermore, 94.3% of patients would undergo another ablation treatment in the same clinic, which reflects that the ablation procedure per se is creating a momentum of confidence between the patient and the treating physician. This confidence level is not substantially dependent whether recurrence rate of symptomatic arrhythmia is high (like in AFIB treatment) or low (like in AVNRT treatment). AFIB patients would go to the same hospital and physician in 92.6% (arrhythmia free in 54.4%) for another ablation procedure; this 'binding' is as high as in AVNRT where symptomatic recurrencies are much less than in AFIB.
Study limitations
Participation in the registry was voluntary and it could not be ensured that all successive patients are enrolled and that data entered on-site via internet are fully correct. While this may raise suspicion of acute complication underreporting, the published complication rates in a large portion of registry patients (ablated for atrial fibrillation) have passed journal peer review and were compared by the editorialists with the literature and with their own experience, to conclude that the data are entirely believable. 32 The Stiftung IHF, as data manager, did not have access to follow-up documents at ablation centres, and the presented follow-up results have been obtained from patients. Information concerning non-fatal events during follow-up is restricted to survivors. No uniform ablation endpoints or methods of arrhythmia monitoring were enforced; although this mirrors routine clinical practice, the primary and long-term ablation success rates should be interpreted with caution.
Conclusions
Ablation therapy is a very safe procedure both acutely and in followup. Although periprocedural success rate has approached 100%, late arrhythmia recurrence affected 32.6% of patients and necessitated repeat ablation in 12.0%. Patients with arrhythmia recurrence can have symptomatic improvement and be satisfied or partly satisfied with the ablation therapy. Nearly 90% of patients with arrhythmia recurrences would let be treated at the same clinic again. The highest follow-up mortality and non-fatal stroke rates were observed in AFL patients, who apparently need consistent long-term anticoagulation and more medical attention.
